GlassScriptPhysician profile
Aram Isaiants
NPI 1477558120
$564.73
in general payments reported to CMS, 2019-2025
15 companies · $47.42 in 2025
The $47.42 reported for 2025 was less than what a typical Foot & Ankle Surgery provider received nationally (typical 2025 total: $424).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $222 · 2020: $85.72 · 2021: $86.10 · 2022: $31.14 · 2024: $92.81 · 2025: $47.42.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $140.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $140.23 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $178.57 | 2019-2022 | |
| Polynovo North America LLC | $53.02 | 2024 | Novosorb Btm |
| Janssen Pharmaceuticals, INC | $52.52 | 2019-2020 | |
| Acell, INC. | $39.93 | 2019 | |
| Smith+Nephew, INC. | $33.07 | 2019 | |
| Amgen INC. | $26.75 | 2025 | Krystexxa |
| Takeda Pharmaceuticals U.S.A., INC. | $24.40 | 2019 | |
| Genentech USA, INC. | $21.72 | 2019 | |
| Pfizer INC. | $21.70 | 2019 | |
| Organogenesis INC. | $21.40 | 2024 | Apligraf |
| Bioventus LLC | $20.67 | 2025 | Exogen Ultrasound Bone Healing System |
| Novo Nordisk INC | $20.02 | 2021 | |
| Depuy Synthes Sales INC. | $18.39 | 2024 | |
| Linvatec Corporation | $16.93 | 2019 | |
| Ironwood Pharmaceuticals, INC | $15.64 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Aram Isaiants listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.